ArticleJournal for immunotherapy of cancer2024

Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors.

Diwakar Davar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.